Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD)
ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ — Innovent Biologics, Inc. ("Innovent")…
Supermicro Grows AI Optimized Product Portfolio with a New Generation of Systems and Rack Architectures Featuring New NVIDIA Blackwell Architecture Solutions
Powerful and Energy Efficient Solutions for Large Scale CSPs and NSPs Incorporate a…